Renal replacement therapy case study

In a retrospective, case-matched control study of 43 patients who received aerosolized and intravenous colistin, who were matched with 43 patients who received intravenous colistin alone, eight in each group developed nephrotoxicity [107. None required renal replacement therapy or withdrawal of colistin. There were no respiratory adverse reactions in those who received aerosolized colistin. 

---